2019 Volume 68 Issue 4 Pages 650-655
Currently, on the basis of the western blotting assay, we use ‘Problot HTLV-I’ for the anti-human T-cell leukemia virus type I (HTLV-I) antibody to confirm the diagnosis of HTLV-I. However, this method has a major disadvantage in terms of its high judgement pending rate. We performed basic evaluation studies of the reagent ‘INNO-LIA HTLV’ for anti-HTLV-I antibody measurement on the basis of the line blotting immunoassay. The within-run and between-day precisions of antibody titer determination by the visual evaluation of this reagent were within the range of ±1 titer step. The concordance of the positive rate for the reagent ‘INNO-LIA HTLV’ was 100.0%. However, the concordance of the negative rate was 66.7% for the pending judgment. As for the pending judgment, the amount of the reagent ‘INNO-LIA HTLV’ decreased with 12 out of 78 specimens compared with 20 out of 78 specimens using the reagent ‘Problot HTLV’. This study revealed that the reagent ‘INNO-LIA HTLV’ is suitable for routine tests.
